Gochman, E., Mahajna, J
These groups often lack effective treatment options, meaning that a new therapy that fulfils an unmet need could quickly gain traction and help address a critical gap in care
Bottom Line The semaglutide patent expiry has handed Indian pharma a rare set-up , a high-growth therapeutic category, a globally recognised molecule, and a head start of nearly six years over the markets that ultimately matter most
Available in 3mg, 7mg, and 14mg doses, Semgo 3mg is an essential medication for improving glycemic control and supporting long-term health
Insatiable demand With both Lilly and Novo seeking to demonstrate the health value of their drugs, it looks likely that demand and hence pressure on the supply chain is unlikely to ease anytime soon
Hlebowicz, J., Hlebowicz, A., Lindstedt, S., Bjrgell, O., Hglund, P., Holst, J